Chinese regulators are ratcheting up their scrutiny of corruption at drug and medical device makers and their agents that do business in the country and putting some companies on a blacklist that limits or bars them from selling products in the country.
China’s National Health and Family Planning Commission (NHFPC), the agency responsible for improving medical and healthcare services in the country, published the new rule last month, which creates a two-tier blacklist system.
